{"denoms":[{"counts":[{"groupId":"BG000","value":"226"},{"groupId":"BG001","value":"227"},{"groupId":"BG002","value":"453"}],"units":"Participants"}],"groups":[{"description":"Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles","id":"BG000","title":"Ripretinib"},{"description":"Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.","id":"BG001","title":"Sunitinib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"145"},{"groupId":"BG001","value":"143"},{"groupId":"BG002","value":"288"}],"title":"18-64 years"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"122"}],"title":"65-74 years"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"43"}],"title":"75 years and older"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"172"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"281"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"28"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"58"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"300"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"60"}],"title":"Not Report"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"131"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"259"}],"title":"ECOG Score 0"},{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"190"}],"title":"ECOG Score 1"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"ECOG Score 2"}]}],"description":"An ECOG Score of 0 means the participant is fully active, able to carry on all pre-disease performance without restriction\n\nECOG Score of 1 means the participant is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work\n\nECOG Score of 2 means the participant is ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Score at Screening","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"59"}],"title":"KIT Exon 9"},{"measurements":[{"groupId":"BG000","value":"167"},{"groupId":"BG001","value":"169"},{"groupId":"BG002","value":"336"}],"title":"KIT Exon 11"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"30"}],"title":"KIT/PDGFRA WT"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"28"}],"title":"Other KIT (absence of Exon 9 or 11)/PDGFRA"}]}],"description":"Electronic Data Capture (EDC) is a system used to capture patient information in a clinical trial. The data is presented based on how many participants had the KIT proto-oncogene receptor tyrosine kinase (KIT) Exon 9 mutation, KIT Exon 11 mutation, the KIT/platelet-derived growth factor receptor alpha (PDGFRA) wild type (WT) mutation, or other KIT (absence of Exon 9 or 11)/PDGFRA mutations.","paramType":"COUNT_OF_PARTICIPANTS","title":"Mutation Type per Electronic Data Capture (EDC)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"34"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"211"},{"groupId":"BG001","value":"208"},{"groupId":"BG002","value":"419"}],"title":"No"}]}],"description":"Electronic Data Capture (EDC) is a system used to capture patient information in a clinical trial. The data is presented based on participants that were intolerant to imatinib or not.","paramType":"COUNT_OF_PARTICIPANTS","title":"Intolerance to Imatinib per Electronic Data Capture (EDC)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"60"}],"title":"KIT Exon 9"},{"measurements":[{"groupId":"BG000","value":"163"},{"groupId":"BG001","value":"164"},{"groupId":"BG002","value":"327"}],"title":"KIT Exon 11"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"33"}],"title":"KIT/PDGFRA wild type (WT)"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"33"}],"title":"Other KIT (absence of Exon 9 or 11)/PDGFRA"}]}],"description":"Interactive Response Technology (IRT) is a randomization and trial supply system that randomly assigns patients to one of the study treatments and supplies study drug. The data is presented based on the participant's Mutational Status: KIT exon 9 mutation; KIT exon 11 mutation; KIT/PDGFRA wild type (WT); or other KIT (absence of exon 9 or 11)/PDGFRA mutations","paramType":"COUNT_OF_PARTICIPANTS","title":"Mutation Type per Interactive Response Technology (IRT)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"45"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"204"},{"groupId":"BG001","value":"204"},{"groupId":"BG002","value":"408"}],"title":"No"}]}],"description":"Interactive Response Technology (IRT) is a randomization and trial supply system that randomly assigns patients to one of the study treatments and supplies study drug. The data is presented based on whether the participants were intolerant to imatinib or not.","paramType":"COUNT_OF_PARTICIPANTS","title":"Intolerance to Imatinib per Interactive Response Technology (IRT)","unitOfMeasure":"Participants"}]}